Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome: Findings From a Phase 1a Trial.

Autor: Derebail VK; UNC Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: vimal_derebail@med.unc.edu., Zhu J; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Crawford ML; Laboratory Corporation of America, Burlington, North Carolina., Garnier JR; Laboratory Corporation of America, Burlington, North Carolina., Martin KA; Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Evanston, Illinois., Skinner S; UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Patel T; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Froment A; UNC Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Sketch MR; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Szeto AH; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Patel SM; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Torrice CD; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Tiefenbacher S; Colorado Coagulation, Laboratory Corporation of America, Englewood, Colorado., Adcock DM; Laboratory Corporation of America, Burlington, North Carolina., Grant RP; Laboratory Corporation of America, Burlington, North Carolina., Key NS; UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Division of Hematology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Crona DJ; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Pharmacy, UNC Medical Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: daniel.crona@unc.edu.
Jazyk: angličtina
Zdroj: American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] 2023 Mar; Vol. 81 (3), pp. 373-376. Date of Electronic Publication: 2022 Nov 01.
DOI: 10.1053/j.ajkd.2022.09.011
Databáze: MEDLINE